Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFRT790M-Mutated NSCLC: A Phase 2b Study

Authors :: Shi, Yuankai
Wu, Shiman
Wang, Ke
Cang, Shundong
Yao, Wenxiu
Fan, Yun
Wu, Lin
Huang, Meijuan
Li, Xingya
Pan, Yueyin
Yang, Zhixiong
Zhu, Bo
Chen, Gongyan
Shi, Jianhua
Sun, Meili
Fang, Jian
Wang, Lijun
Chen, Zhaohong
Liu, Chunling
Li, Jingzhang
Liu, Jiwei
Sun, Shenghua
Zhao, Yanqiu
Guo, Yanzhen
Meng, Zili
Liu, Zhefeng
Han, Zhigang
Lu, Hong
Ma, Rui
Hu, Sheng
Zhao, Guofang
Liu, Zheng
Xie, Congying
Zhong, Diansheng
Zhao, Hui
Yu, Huiqing
Zhang, Longzhen
Bi, Minghong
Yi, Shanyong
Guo, Shuliang
Yi, Tienan
Li, Wen
Lin, Yingcheng
Shu, Yongqian
Chen, Zhendong
Guo, Zhongliang
Greco, Michael
Wang, Tingting
Shen, Haijiao
Source :: Journal of Thoracic Oncology; November 2022, Vol. 17 Issue: 11 p1306-1317, 12p
Publication Year :: 2022
Abstract: Rezivertinib (BPI-7711) is a novel third-generation EGFRtyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFRT790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/recurrent EGFRT790M-mutated NSCLC.

Full Text Access

Tools